Nanosphere Announces Positive New Data Presented at the Annual Meeting of the American Urological Association Demonstrates Clinical Use for Nanosphere's Ultra-Sensitive PSA Assay

Positive clinical studies using Nanosphere Inc.'s NSPH Verisens™ ultra-sensitive PSA assay were presented in moderated poster sessions at the annual meeting of the American Urological Association. The test differentiated men with recurrent cancer from men with no recurrence in a study of 367 men. The Verisens PSA assay tests for a single, well-known biomarker in blood. The company believes this has a number of advantages over other methods. A small amount of blood is used, rather than biopsied tissue. Using a single biomarker does not require complex algorithms in contrast to some multi-marker approaches. Moreover, testing using Nanosphere's ultra-sensitive PSA assay will help reduce the rising healthcare cost burden associated with unnecessary biopsies and complex genetic lab tests.